These studies demonstrated that both mechanisms inherent to Her2-bridging CAR-CD19 T cells were active in vivo: the T cells could eliminate CD19-positive Nalm6 cells directly via the CAR-CD19 domain and also indirectly, via recognition of the CD19 ECD on the bridging protein that bound to the Her2-positive tumor cells. The gene discussed is ERBB2; the disease is neoplasm.